Novel leukemic cell lines resistant to clofarabine by mechanisms of decreased active metabolite and increased antiapoptosis

Cancer Science

Volumn 104, Issue 6, 2013, Pages 732-739

  Shigemi, Hiroko ^a   Yamauchi, Takahiro ^a   Tanaka, Yukie ^a   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS DNA; CLOFARABINE; DEOXYCYTIDINE KINASE; DEOXYGUANOSINE KINASE; DRUG METABOLITE; MESSENGER RNA; MITOCHONDRIAL DNA; NUCLEOSIDE; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NUCLEOSIDE TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENINE NUCLEOTIDES; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HL-60 CELLS; HUMANS; LEUKEMIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84878204741     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12131     Document Type: Article

References (41)

1. Gaynon PS, Trigg ME, Heerema NA et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000; 14: 2223-33.
2. Jeha S, Gandhi V, Chan KW et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004; 103: 784-9.
3. Appelbaum FR, Gundacker H, Head DR et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481-5.
4. Burnett AK, Mohite U. Treatment of older patients with acute myeloid leukemia - new agents. Semin Hematol 2006; 43: 96-106.
5. Parker WB. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev 2009; 109: 2880-93.
6. Parker WB, Shaddix SC, Chang CH et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-/3-d-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribo-nucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res 1991; 51: 2386-94.
7. Karp JE, Ricklis RE, Balakrishnan K et al. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007; 110: 1762-9.
8. Kantarjian H, Gandhi V, Cortes J et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003; 102: 2379-86.
9. Kantarjian HM, Gandhi V, Kozuch P et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003; 21: 1167-73.
10. Cooper T, Kantarjian H, Plunkett W, Gandhi V. Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1417-23.
11. King KM, Damaraju VL, Vickers MF et al. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol Pharmacol 2006; 69: 346-53.
12. Zhenchuk A, Lotfi K, Juliusson G, Albertioni F. Mechanisms of anticancer action and pharmacology of clofarabine. Biochem Pharmacol 2009; 78: 1351-9.
13. Genini D, Adachi S, Chao Q et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000; 96: 3537-43.
14. Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003; 22: 9063-74.
15. Lotfi K, Månsson E, Spasokoukotskaja T et al. Biochemical pharmacology and resistance to 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res 1999; 5: 2438-44.
16. Parker WB, Shaddix SC, Rose LM et al. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-b-d-arabinofuranosyl) adenine, 2-chloro-9-(2-deoxy-2-fluoro-b-d-ribofuranosyl) adenine, and 2-chloro-9-(2-deoxy-2, 2-difluoro-b-d-ribofuranosyl) adenine in CEM Cells. Mol Pharmacol 1999; 55: 515-20.
17. Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-β-d-arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res 1995; 55: 2847-52.
18. Negoro E, Yamauchi T, Urasaki Y, Nishi R, Hori H, Ueda T. Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses. Int J Oncol 2011; 38: 911-9.
19. Yamauchi T, Negoro E, Kishi S et al. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5′-nucleotidase II expression ratio in primary acute myeloid leukemia cells. Biochem Pharmacol 2009; 77: 1780-6.
20. Wiley JS, Jones SP, Sawyer WH, Paterson ARP. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J Clin Invest 1982; 69: 479-89.
21. Yoshio N, Kawai Y, Hori H, Ueda T. Resistance to 9-beta-d-arabinofuranosyl-2-fluoroadenine due to reduced incorporation into DNA from competition by excess deoxyadenosine triphosphate: implications for different sensitivities to nucleoside analogues. Int J Hematol 2005; 81: 405-12.
22. Yamauchi T, Ueda T. Determination of clofarabine triphosphate concentrations in leukemia cells using sensitive, isocratic high-performance liquid chromatography. Anticancer Res 2011; 31: 2863-7.
23. Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001; 7: 3580-9.
24. Zhao L, Wientjes MG, Au JL. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004; 10: 7994-8004.
25. Zhu C, Johansson M, Karlsson A. Incorporation of nucleoside analogs into nuclear or mitochondrial DNA is determined by the intracellular phosphorylation site. J Biol Chem 2000; 275: 26727-67.
26. Damaraju VL, Damaraju S, Young JD et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 2003; 22: 7524-36.
27. Sartorius UA, Krammer PH. Upregulation of Bcl2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 2002; 97: 584-92.
28. van Delft MF, Wei AH, Mason KD et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389-99.
29. Trudel S, Stewart AK, Li Z et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res 2007; 13: 621-9.
30. Garcia-Carbonero R, Ryan DP, Chabner BA. Cytidine analogs. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy. Philadelphia, PA: Lippincott-Raven Publishers, 1996; 265-94.
31. Huigsloot M, Tijdens IB, Mulder GJ, van de Water B. Differential regulation of doxorubicin-induced mitochondrial dysfunction and apoptosis by Bcl-2 in mammary adenocarcinoma (MTLn3) cells. J Biol Chem 2002; 277: 35869-79.
32. Takahashi M, Saito H, Atsukawa K, Ebinuma H, Okuyama T, Ishii H. Bcl-2 prevents doxorubicin-induced apoptosis of human liver cancer cells. Hepatol Res 2003; 25: 192-201.
33. Karpinich NO, Tafani M, Schneider T, Russo MA, Farber JL. The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J Cell Physiol 2002; 19: 16547-52.
34. Månsson E, Spasokoukotskaja T, Sällström J, Eriksson S, Albertioni F. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line. Cancer Res 1999; 59: 5956-63.
35. Månsson E, Liliemark E, Söderhäll S, Gustafsson G, Eriksson S, Albertioni F. Real-time quantitative PCR assays for deoxycytidine kinase, deoxyguanosine kinase and 5′-nucleotidase mRNA measurement in cell lines and in patients with leukemia. Leukemia 2002; 16: 386-92.
36. Bhat UG, Gartel AL. Nucleoside analog ARC targets Mcl-1 to induce apoptosis in leukemia cells. Leukemia 2010; 24: 851-5.
37. Kohl TM, Hellinger C, Ahmed F et al. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia 2007; 21: 1763-72.
38. Whitecross KF, Alsop AE, Leonie A et al. Defining the target specificity ofABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood 2009; 113: 1982-91.
39. Hann CL, Daniel VC, Sugar EA et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 2008; 68: 2321-8.
40. Ugarenko M, Nudelman A, Rephaeli A et al. ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts. Biochem Pharmacol 2010; 79: 339-49.
41. Månsson E, Flordal E, Liliemark J et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol 2003; 65: 237-47.